Semaglutide vs Tirzepatide: A Detailed Comparison

Semaglutide is a selective GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor, regulating appetite, glucose homeostasis, and metabolic function through GLP-1 signaling. Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual mechanism is the primary pharmacological distinction between the drugs. Both are administered subcutaneously once weekly for weight management and diabetes, but their receptor selectivity profiles lead to different efficacy profiles.

Tirzepatide (marketed as Mounjaro for diabetes, Zepbound for weight management in the US) received FDA approval for type 2 diabetes in May 2022 and weight management in November 2023—approximately 5 and 2 years after semaglutide's respective approvals. Both drugs are now available in major developed markets; tirzepatide is increasingly used as an alternative to semaglutide or as a subsequent therapy for patients with insufficient response to semaglutide monotherapy.

Semaglutide's mechanism is well-characterised: GLP-1 receptor activation in the hypothalamus suppresses appetite; in the pancreas, it promotes glucose-dependent insulin secretion and suppresses glucagon; in the gastrointestinal tract, it slows gastric emptying and enhances satiety signalling. The mechanism has been validated through multiple pathways, and the relative contributions of central versus peripheral effects are understood.

Tirzepatide adds GIP receptor agonism to the GLP-1 agonism. GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that enhances insulin secretion in response to oral nutrient intake. GIP receptor agonism has been shown in preclinical studies to promote weight loss through appetite suppression mechanisms potentially complementary to GLP-1 signaling, enhance glucose-dependent insulin secretion independently of GLP-1, and promote insulin sensitivity. The dual agonism of tirzepatide is hypothesised to produce greater weight loss and glycaemic benefit than GLP-1 monotherapy, though the relative contribution of GIP versus GLP-1 to clinical outcomes is incompletely characterised.

In head-to-head clinical trials comparing semaglutide and tirzepatide, tirzepatide consistently demonstrated superior weight loss. The SURPASS program (tirzepatide diabetes trials) showed HbA1c reductions of 1.5–2.0 percentage points depending on dose. The SURMOUNT program (tirzepatide weight management trials) demonstrated weight loss of 22–23% from baseline with tirzepatide 15 mg (the highest approved dose) versus 15–17% with semaglutide 2.4 mg. However, direct head-to-head comparisons of equivalent doses are limited; most comparisons are indirect (comparing trial results across different studies).

For type 2 diabetes, tirzepatide's HbA1c reductions (1.5–2.0%) slightly exceed semaglutide's (1.0–1.8%), though the difference is modest and may not be clinically significant for individual patients. For weight management, tirzepatide's approximately 6–8 percentage point greater weight loss compared to semaglutide is more clinically substantial, suggesting that GIP/GLP-1 agonism is more potent than GLP-1 agonism alone for weight loss. This distinction has important implications for treatment selection, particularly in patients inadequately responding to semaglutide monotherapy.

Both semaglutide and tirzepatide share the same common adverse events: gastrointestinal side effects (nausea, vomiting, diarrhoea, constipation) are most frequent, occurring in 25–40% of treated participants. Discontinuation rates due to gastrointestinal intolerance are similar (~4–8% in trials). However, some observational data suggest that tirzepatide may be associated with higher rates of gastrointestinal side effects, particularly nausea, compared to semaglutide, though definitive comparative data are limited.

Both drugs carry the black-box thyroid C-cell warning based on preclinical rodent studies; neither has demonstrated increased thyroid cancer in clinical use. Pancreatitis, gallbladder disease, and serious adverse events occur at similar frequencies in both drugs. Heart rate increases are similar (2–3 bpm). Cardiovascular outcome trials (SUSTAIN-6 and SELECT for semaglutide; the SUMMIT trial for tirzepatide in weight management) have demonstrated cardiovascular benefit for both agents. Overall, the safety profiles are comparable, with gastrointestinal tolerability being the primary limiting factor for both.

Semaglutide's evidence base is more extensive: STEP program (4,500+ weight management participants), SUSTAIN program (13,000+ diabetes participants), and SELECT trial (17,600+ cardiovascular outcomes). This comprehensive evidence base was established before approval and has been supplemented by post-marketing surveillance data spanning millions of patient-years of use. Semaglutide has longer real-world follow-up (5+ years in clinical practice; 20+ years for the GLP-1 agonist class).

Tirzepatide's evidence base, while robust, is newer: SURPASS program (diabetes trials) and SURMOUNT program (weight management trials) with similar participant numbers to STEP/SUSTAIN, but shorter follow-up (2–3 years maximum). The SUMMIT trial demonstrated cardiovascular benefit in weight management. Longer-term (5+ years) safety and efficacy data for tirzepatide are emerging; real-world experience is limited. This age difference means semaglutide has a longer safety track record, which may influence prescriber confidence or patient preference.

Both semaglutide and tirzepatide are approved by major regulatory agencies (FDA, EMA, TGA, Health Canada) for type 2 diabetes and chronic weight management. In Australia, both are available: Ozempic (semaglutide diabetes, PBS-listed) and Wegovy (semaglutide weight management, private prescription) are competing with Mounjaro (tirzepatide diabetes, likely PBS-listed) and Zepbound (tirzepatide weight management, private prescription). Prescriber choice between the drugs is generally unrestricted in most countries; clinical decision-making is based on efficacy, safety tolerance, cost, and patient preference.

Cost considerations vary by jurisdiction. In the US, Wegovy and Zepbound have similar high out-of-pocket costs (~USD 1,000/month). In Australia, Ozempic (diabetes) is PBS-subsidised while Wegovy is private; tirzepatide's PBS status for diabetes and weight management indications is evolving. These cost differences may influence real-world treatment selection in some patients.